Sugi Predict

Sugi Predict / Compounds / SCHEMBL7028984

SCHEMBL7028984

SCHEMBL7028984

CC(C)(C)c1nc2cc(N)ccc2[nH]1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.50
▸ MAPT P10636 6/20 0.50
▸ ALDH1A1 P00352 4/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ SCN10A Q9Y5Y9 2/20 0.45
▸ KCNH2 Q12809 2/20 0.45
▸ MAPKAPK2 P49137 1/20 0.45
▸ RPS6KA3 P51812 1/20 0.45
▸ CSNK2A1 P68400 1/20 0.45
▸ PLK3 Q9H4B4 1/20 0.45
▸ CYP2A6 P11509 1/20 0.42
▸ KEAP1 Q14145 1/20 0.42
▸ MEN1 O00255 4/20 0.39
▸ KMT2A Q03164 4/20 0.39
▸ F2 P00734 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CHRM2 P08172 1/20 0.39
▸ HTR1A P08908 1/20 0.39
▸ ADRA2A P08913 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL521629 0.86 MAPT (0.68) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL1131972 0.82 MAPT (0.73) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL23619188 0.81 ALDH1A1 (0.47) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL846855 0.80 SCN10A (0.58) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL10005347 0.80 ALDH1A1 (0.46) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL14491782 0.79 ALDH1A1 (0.45) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL2732982 0.79 ALDH1A1 (0.45) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL13264167 0.79 ALDH1A1 (0.45) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL10248397 0.79 SMN1; SMN2 (0.45) ALDH1A1L3MBTL1SMN1; SMN2SCN10AKCNH2
SCHEMBL18727321 0.78 ALDH1A1 (0.42) KDM4EMAPTALDH1A1L3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552770-B2 Compounds for treating respiratory disease TMEM16A LIMITED (GB) 2026-02-17 — — US disclosed
US-20220098167-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM16A LTD (GB) 2022-03-31 — — US disclosed
WO-2020249957-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE Enterprise Therapeutics Limited (GB) 2020-12-17 — — WO disclosed
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof D. E. SHAW RESEARCH, LLC 2020-10-01 — — US disclosed
US-20030181730-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2003-09-25 — — US disclosed
US-20030022927-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2003-01-30 — — US disclosed
US-6495583-B1 DRUG FOR TREATING AN ALPHA-2 ADRENERGIC RECEPTOR ASSOCIATED DISORDER, NASAL CONGENSTION AND ALLEVIATING PAIN SYNAPTIC PHARMACEUTICAL CORPORATION 2002-12-17 — — US disclosed
US-6436982-B1 USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2002-08-20 — — US disclosed
US-20020072536-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2002-06-13 — — US disclosed
US-6403626-B1 USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2002-06-11 — — US disclosed
US-20020065307-A1 Novel benzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION 2002-05-30 — — US disclosed
US-6316637-B1 SELECTIVE FOR CLONED HUMAN ALPHA 2 RECEPTORS AND ARE USEFUL AS ANALGESIC, SEDATIVE OR ANAESTHETIC AGENTS SYNAPTIC PHARMACEUTICAL CORPORATION 2001-11-13 — — US disclosed
EP-0775134-A4 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMA CORP (US) 1997-08-13 — — EP disclosed
EP-0775134-A1 Imidazolin-2-ylaminobenzimidazole derivatives SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-05-28 — — EP disclosed
WO-1996004270-A1 NOVEL BENZIMIDAZOLE DERIVATIVES SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1996-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552770-B2 Compounds for treating respiratory disease TMEM109, SCN1A, SLC16A1 KDM4E 3063/4885MAPT 1158/4885ALDH1A1 596/4885
US-20020065307-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 KDM4E 1828/4885MAPT 4094/4885ALDH1A1 938/4885
US-20020072536-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 KDM4E 1775/4885MAPT 4095/4885ALDH1A1 923/4885
US-20030022927-A1 Novel benzimidazole derivatives OPRL1, OPRD1, OPRM1 KDM4E 2083/4885MAPT 4207/4885ALDH1A1 1022/4885
US-20200308165-A1 Compounds as Ras Inhibitors and Use Thereof KRAS, NRAS, HRAS KDM4E 3372/4885MAPT 3664/4885ALDH1A1 2215/4885
US-20030181730-A1 Novel benzimidazole derivatives OPRD1, OPRL1, OPRM1 KDM4E 1828/4885MAPT 4094/4885ALDH1A1 938/4885
US-20220098167-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM109, SLC16A1, CFTR KDM4E 3392/4885MAPT 1182/4885ALDH1A1 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.